TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression ...

Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the ...